Statins and primary liver cancer: A meta-analysis of observational studies

Danitza Pradelli, Davide Soranna, Lorenza Scotti, Antonella Zambon, Alberico Catapano, Giuseppe Mancia, Carlo La Vecchia, Giovanni Corrao

Research output: Contribution to journalArticlepeer-review


Statins are among the most commonly prescribed drugs used to manage dyslipidemia. Hepatocellular carcinoma is the third leading cause of cancer mortality and its rates have recently been increasing in central and northern Europe and USA. To quantify the association between statin use and risk for HCC, we performed a meta-analysis of published studies. We conducted a MEDLINE search for observational studies reporting the association between exposure to statins and risk for incident liver cancer until March 2012. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Moreover, between-study heterogeneity and publication bias were assessed using adequate statistical tests. Five observational studies (two case-control and three cohort studies) based on 2574 cases of HCC were included. Statin treatment, compared with no treatment, was inversely related to HCC (summary RR=0.58; 95% CI 0.46-0.74). Between-study heterogeneity was significant (P

Original languageEnglish
Pages (from-to)229-234
Number of pages6
JournalEuropean Journal of Cancer Prevention
Issue number3
Publication statusPublished - May 2013


  • hepatocellular carcinoma
  • liver cancer
  • meta-analysis
  • observational studies
  • statin(s)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Epidemiology
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Statins and primary liver cancer: A meta-analysis of observational studies'. Together they form a unique fingerprint.

Cite this